Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 119 items for :

  • Adverse events x
Clear All
Luisa Paschke Department of Endocrinology and Nephrology, Division of Endocrinology, University Clinic Leipzig, Leipzig, Germany
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Luisa Paschke in
Google Scholar
PubMed Close
,
Thomas Lincke Department of Radiology, Division of Nuclear Medicine, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Thomas Lincke in
Google Scholar
PubMed Close
,
Katja Sibylle Mühlberg Department of Angiology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed Close
,
Wolfram J. Jabs Department of Nephrology, Vivantes Clinics, Berlin, Germany

Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed Close
,
Tom H. Lindner Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Tom H. Lindner in
Google Scholar
PubMed Close
, and
Ralf Paschke Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

What Is Known about This Topic? Both phase III trials of cabozantinib and lenvatinib reported that renal adverse events occurred in rare cases. The phase III study of carbozantinib reported no adverse events (AEs) regarding renal toxicity

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000491387
Volume/Issue:
Volume 7: Issue 6
Free access
J Karmisholt Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark
Department of Clinical Institute, Aalborg University, Aalborg, Denmark

Search for other papers by J Karmisholt in
Google Scholar
PubMed Close
,
S L Andersen Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark

Search for other papers by S L Andersen in
Google Scholar
PubMed Close
,
I Bulow-Pedersen Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark
Department of Clinical Institute, Aalborg University, Aalborg, Denmark

Search for other papers by I Bulow-Pedersen in
Google Scholar
PubMed Close
,
A Krejbjerg Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

Search for other papers by A Krejbjerg in
Google Scholar
PubMed Close
,
B Nygaard Department of Endocrinology and Internal Medicine, Herlev University Hospital, Copenhagen, Denmark

Search for other papers by B Nygaard in
Google Scholar
PubMed Close
, and
A Carlé Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark
Department of Clinical Institute, Aalborg University, Aalborg, Denmark

Search for other papers by A Carlé in
Google Scholar
PubMed Close

patients had an adverse event prompting exclusion from the study. Fifteen patients were excluded due to a lack of compliance with the protocol. The main reason for this was the many blood samples required at certain time points. Three patients were excluded

Article Type:
Research Article
Collections:
Hyperthyroidism and thyrotoxicosis
DOI:
https://doi.org/10.1530/ETJ-22-0031
Volume/Issue:
Volume 11: Issue 3
Open access
Daniela Cavaco Department of Endocrinology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Daniela Cavaco in
Google Scholar
PubMed Close
,
Sara Carvalhal Department of General Surgery, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Sara Carvalhal in
Google Scholar
PubMed Close
, and
Valeriano Leite Department of Endocrinology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed Close

institution and metastases were actively bleeding, imposing urgent care. ECT has the advantage of being performed in an ambulatory surgical unit with only half-day to 1 day of hospital stay and can be repeated several times. Since the most common ECT adverse

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000507888
Volume/Issue:
Volume 9: Issue 4
Free access
Mikael Lantz Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund

Search for other papers by Mikael Lantz in
Google Scholar
PubMed Close
,
Jan Calissendorff Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset

Search for other papers by Jan Calissendorff in
Google Scholar
PubMed Close
,
Frank Träisk Department of Clinical Neurosciences, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden

Search for other papers by Frank Träisk in
Google Scholar
PubMed Close
,
Leif Tallstedt Department of Clinical Neurosciences, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden

Search for other papers by Leif Tallstedt in
Google Scholar
PubMed Close
,
Tereza Planck Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund

Search for other papers by Tereza Planck in
Google Scholar
PubMed Close
,
Ove Törring Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset

Search for other papers by Ove Törring in
Google Scholar
PubMed Close
,
Bengt Hallengren Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund

Search for other papers by Bengt Hallengren in
Google Scholar
PubMed Close
, and
Peter Åsman Department of Endocrinology and Ophthalmology, Skåne University Hospital Malmö, Malmö
Department of Clinical Sciences, Lund University, Lund

Search for other papers by Peter Åsman in
Google Scholar
PubMed Close

related to treatment with methimazole (table 3 ). Other methimazole-related adverse events reported were skin reactions, loss of taste and joint pain/swollenness. None of these events differed significantly between the groups. Gastrointestinal symptoms

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000443373
Volume/Issue:
Volume 5: Issue 1
Free access
Pauline Campredon Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France

Search for other papers by Pauline Campredon in
Google Scholar
PubMed Close
,
Philippe Imbert Ophthalmologist, Clinique du Parc, Toulouse, France
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France

Search for other papers by Philippe Imbert in
Google Scholar
PubMed Close
,
Céline Mouly Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France

Search for other papers by Céline Mouly in
Google Scholar
PubMed Close
,
Solange Grunenwald Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France

Search for other papers by Solange Grunenwald in
Google Scholar
PubMed Close
,
Julien Mazières Department of Pneumology, Larrey University Hospital, Toulouse, France

Search for other papers by Julien Mazières in
Google Scholar
PubMed Close
, and
Philippe Caron Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France

Search for other papers by Philippe Caron in
Google Scholar
PubMed Close

What Is Known about This Topic? Anti-PD-1 monoclonal antibody therapy is associated with immune-related adverse events, and the most frequent is inflammatory thyroiditis. During immunotherapy, immune-related ocular toxicities are

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000485742
Volume/Issue:
Volume 7: Issue 2
Free access
Carla Gambale Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Carla Gambale in
Google Scholar
PubMed Close
,
Alessandro Prete Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Prete in
Google Scholar
PubMed Close
,
Chiara Romei Department of Diagnostic Imaging, Unit of Radiology, Pisa University Hospital, Pisa, Italy

Search for other papers by Chiara Romei in
Google Scholar
PubMed Close
,
Alessandro Celi Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Celi in
Google Scholar
PubMed Close
,
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close
, and
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed Close

inhibitors, atypical adverse events have been described. Novel insights We present the first reported case of obliterative bronchiolitis occurring during treatment with selpercatinib in an advanced RET-mutant medullary thyroid cancer

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0189
Volume/Issue:
Volume 13: Issue 5
Open access
Alice Nervo Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Alice Nervo in
Google Scholar
PubMed Close
,
Alberto Ragni Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Alberto Ragni in
Google Scholar
PubMed Close
,
Alessandro Piovesan Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Alessandro Piovesan in
Google Scholar
PubMed Close
,
Valentina Marica Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Valentina Marica in
Google Scholar
PubMed Close
,
Enrica Migliore Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Enrica Migliore in
Google Scholar
PubMed Close
,
Marco Gallo Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Marco Gallo in
Google Scholar
PubMed Close
, and
Emanuela Arvat Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Emanuela Arvat in
Google Scholar
PubMed Close

-life setting [ 1 - 4 ]. Nevertheless, frequent onset of adverse events (AEs) may decrease patients’ compliance and, in some cases, lead to discontinuation of therapy [ 5 ]. In recent years, growing interest has been dedicated to the study of the quality of

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000508186
Volume/Issue:
Volume 10: Issue 1
Free access
Carla Colombo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed Close
,
Daniele Ceruti Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed Close
,
Simone De Leo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed Close
,
Grzegorz Bilo Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed Close
,
Matteo Trevisan Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed Close
,
Noemi Giancola Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Noemi Giancola in
Google Scholar
PubMed Close
,
Claudia Moneta Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed Close
,
Gianfranco Parati Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Gianfranco Parati in
Google Scholar
PubMed Close
,
Luca Persani Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed Close
, and
Laura Fugazzola Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close

demonstrated significantly prolonged progression-free survival (PFS) ( 4 , 5 , 6 , 7 , 8 ). The occurrence of several adverse events (AEs) has been reported, particularly during treatment with anti-angiogenic drugs: hypertension (HTN), diarrhoea

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0047
Volume/Issue:
Volume 12: Issue 4
Open access
Jaume Capdevila Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain

Search for other papers by Jaume Capdevila in
Google Scholar
PubMed Close
,
Desiree’ Deandreis Department of Medical Sciences, Nuclear Medicine Unit, University of Turin, AOU Città della Salute e della Scienza, Turin, Italy

Search for other papers by Desiree’ Deandreis in
Google Scholar
PubMed Close
,
Cosimo Durante Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

Search for other papers by Cosimo Durante in
Google Scholar
PubMed Close
,
Sophie Leboulleux Service of Endocrinology, Diabetology, University Hospital Geneve, Geneve, Switzerland

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close
,
Markus Luster Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany

Search for other papers by Markus Luster in
Google Scholar
PubMed Close
,
Romana Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed Close
,
Kate Newbold Royal Marsden Hospital, London, United Kingdom

Search for other papers by Kate Newbold in
Google Scholar
PubMed Close
,
Susanne Singer Institute of Medical Biostatistics Epidemiology and Informatics (IMBEI), University Medical Center of Johannes Gutenberg University, Mainz, Germany

Search for other papers by Susanne Singer in
Google Scholar
PubMed Close
,
Gerasimos P Sykiotis Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Search for other papers by Gerasimos P Sykiotis in
Google Scholar
PubMed Close
,
Beate Bartes Association “Vivre sans Thyroïde”, Léguevin, France

Search for other papers by Beate Bartes in
Google Scholar
PubMed Close
,
Kate Farnell Butterfly Thyroid Cancer Trust, Rowlands Gill, Tyne & Wear, UK

Search for other papers by Kate Farnell in
Google Scholar
PubMed Close
, and
Laura Deborah Locati Medical Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy
Department of Internal Medicine and Therapeutics, University of Pavia, Italy

Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed Close

no BRAF/MEK inhibitors have been approved up to now in Europe. Since MKIs are associated with substantial adverse events (AEs) such as hypertension, diarrhea, fatigue, and weight loss, and since they are expected to be administered on a long-term term

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0068
Volume/Issue:
Volume 12: Issue 5
Open access
Liyun Shen Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Liyun Shen in
Google Scholar
PubMed Close
,
Lei Ye Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Lei Ye in
Google Scholar
PubMed Close
,
Wei Zhu Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Wei Zhu in
Google Scholar
PubMed Close
,
Qin Jiao Department of Ophthalmology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Qin Jiao in
Google Scholar
PubMed Close
,
Yulin Zhou Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Yulin Zhou in
Google Scholar
PubMed Close
,
Shu Wang Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Shu Wang in
Google Scholar
PubMed Close
,
Weiqing Wang Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Weiqing Wang in
Google Scholar
PubMed Close
, and
Guang Ning Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Guang Ning in
Google Scholar
PubMed Close

th week). Secondary outcomes were the adverse events (AEs) and other individual ophthalmic parameters. We also examined the overall response at week 12 as a post hoc outcome. All patients underwent ophthalmic, endocrine, and safety assessments at

Article Type:
Research Article
Collections:
Thyroid autoimmunity
DOI:
https://doi.org/10.1530/ETJ-22-0017
Volume/Issue:
Volume 11: Issue 5
Open access